Drugs / REC617
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07633756 | Oct 2026 → Dec 2029 expected | leiomyosarcoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REC-617 | “A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy” NCT07633756 ↗ |
| Action | Inhibit | “Selective CDK7 Inhibitor” NCT07633756 ↗ |
| Route | Oral | “Given by PO” NCT07633756 ↗ |
| Target | CDK7 | “Selective CDK7 Inhibitor” NCT07633756 ↗ |